- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03839433
The Mannitol-Asthma-Ciclesonide-Study (MACS)
July 23, 2019 updated by: Prof. Dr. Jörg Leuppi, Cantonal Hosptal, Baselland
Ciclesonide for the Treatment of Airway Hyperresponsiveness: The Mannitol-Asthma-Ciclesonide-Study
Response of a 4 weeks treatment with daily once 320 µg ciclesonide on airway hyperresponsiveness assessed with mannitol.
Hypothesis: Treatment with inhaled ciclesonide reduces airway hyper-responsiveness in 80% of hyper-responsive patients compared to 20% only in the placebo group and the group without airway hyper-responsiveness.
Study Overview
Study Type
Interventional
Enrollment (Actual)
72
Phase
- Phase 4
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 70 years (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Referred to the pulmonology department of the university hospital Basel because of suspected asthma defined as respiratory symptoms like wheezing or cough or chest tightness.
- Asthma symptoms partly controlled according to GINA (Global Initiative for Asthma, October 2006) 1 week prior to randomization
- FEV1 ≥ 70% predicted
Exclusion Criteria:
- Smoker and ex-smoker with >10 pack years
- COPD (chronic obstructive pulmonary disease)
- Upper respiratory tract infection within the past 4 weeks.
- ICS or oral steroids during the previous month before inclusion
- beta-blockers within the past 4 weeks
- Current treatment with medication as defined in section concomitant medication (ICS other than study medication, ß-blockers)
- Pregnancy
- Known malignancy
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: DOUBLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
ACTIVE_COMPARATOR: ciclesonide positive
Half of the Mannitol positive patients were given ciclesonide.
Half of the Mannitol negative patients were given ciclesonide.
All patients in the "ciclesonide positive" arm received ciclesonide.
|
|
PLACEBO_COMPARATOR: Placebo
Half of the Mannitol positive patients were given a placebo.
Half of the Mannitol negative patients were given a placebo.
All patients in the "placebo" arm received placebo.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change of hyperresponsiveness to mannitol by measuring PD15 FEV1 after 4 weeks (improvement of more than at least 1.5 doubling dose)
Time Frame: 4 weeks
|
measurements of PD15 FEV1 (provocative dose to produce a 15% fall in FEV1), bronchial hyperresponsiveness.
A 15 % reduction of FEV1 means a bronchial hyperresponsiveness
|
4 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in PD20 FEV1 methacholine (Responsiveness to metacholine)
Time Frame: 4 weeks
|
measurements of PD20 FEV1 (provocative dose to produce a 20% fall in FEV1) bronchial hyperresponsiveness.
A 20 % reduction of FEV1 means a bronchial hyperresponsiveness
|
4 weeks
|
Change in FeNO (Nitric Oxide)
Time Frame: 4 weeks
|
Measurement of bronchial inflammation.
It determines the level of nitric oxide in parts per billion (PPB).
Nitric oxide in exhaled air is another marker of airway inflammation.
Subjects with atopic asthma or rhinitis seem to have elevated expiratory nitric oxide (eNO) levels.
|
4 weeks
|
Change in ACQ (Asthma Control Questionnaire)
Time Frame: 4 weeks
|
It measures both the adequacy of asthma control and change in asthma control, which occurs either spontaneously or as a result of treatment.
It measures both the adequacy of asthma control and change in asthma control, which occurs either spontaneously or as a result of treatment.
The ACQ has 7 questions (the top scoring 5 symptoms, FEV1% pred.
and daily rescue bronchodilator use).
Patients are asked to recall how their asthma has been during the previous week and to respond to the symptom and bronchodilator use questions on a 7-point scale (0=no impairment, 6= maximum impairment).
Clinic staff score the FEV1% predicted on a 7-point scale.
The questions are equally weighted and the ACQ score is the mean of the 7 questions and therefore between 0 (totally controlled) and 6 (severely uncontrolled).
|
4 weeks
|
AQLQ (Asthma Quality of Life Questionnaire)
Time Frame: 4 weeks
|
The Asthma Quality of Life Questionnaire (AQLQ) was developed to measure the functional problems (physical, emotional, social and occupational) that are most troublesome to adults (17-70 years) with asthma.
There are 32 questions in the AQLQ and they are in 4 domains (symptoms, activity limitation, emotional function and environmental stimuli).
The activity domain contains 5 'patient-specific' questions.
This allows patients to select 5 activities in which they are most limited and these activities will be assessed at each follow-up.
Patients are asked to think about how they have been during the previous two weeks and to respond to each of the 32 questions on a 7-point scale (7 = not impaired at all - 1 = severely impaired).
The overall AQLQ score is the mean of all 32 responses and the individual domain scores are the means of the items in those domains.
|
4 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
June 1, 2007
Primary Completion (ACTUAL)
August 1, 2008
Study Completion (ACTUAL)
August 1, 2008
Study Registration Dates
First Submitted
August 4, 2017
First Submitted That Met QC Criteria
February 11, 2019
First Posted (ACTUAL)
February 15, 2019
Study Record Updates
Last Update Posted (ACTUAL)
July 25, 2019
Last Update Submitted That Met QC Criteria
July 23, 2019
Last Verified
July 1, 2019
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Respiratory Tract Diseases
- Immune System Diseases
- Lung Diseases
- Hypersensitivity, Immediate
- Bronchial Diseases
- Lung Diseases, Obstructive
- Respiratory Hypersensitivity
- Hypersensitivity
- Asthma
- Physiological Effects of Drugs
- Glucocorticoids
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Anti-Allergic Agents
- Ciclesonide
Other Study ID Numbers
- BY 9010 / CH-101
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Asthma, Bronchial
-
Vanderbilt University Medical CenterNot yet recruitingAsthma in Children | Asthma Attack | Asthma Acute | Acute Asthma Exacerbation | Asthma; StatusUnited States
-
University of California, San FranciscoCompletedAsthma in Children | Asthma Attack | Asthma Acute | Asthma ChronicUnited States
-
SamA Pharmaceutical Co., LtdCompleted
-
Johann Wolfgang Goethe University HospitalCompleted
-
AstraZenecaRecruitingBronchial Asthma (Only the Patients With Severe or Intractable Bronchial Asthma Which Could Not be Controlled With the Existing Therapy)Japan
-
Astellas Pharma IncAstellas Pharma Europe B.V.CompletedAsthma, Bronchial | Bronchial AsthmaRussian Federation, Poland, Germany, Ukraine, Czech Republic
-
Astellas Pharma IncAstellas Pharma Europe B.V.CompletedAsthma, Bronchial | Bronchial AsthmaRussian Federation, Hungary, Germany, Poland, Bulgaria, Ukraine, Czech Republic
-
Value Outcomes Ltd.AstraZenecaCompletedAsthma, Bronchial | Bronchial Asthma | Asthma Chronic | Asthma; EosinophilicCzechia
-
Parc de Salut MarActive, not recruitingAsthma in Children | Persistent Asthma | Asthma ExacerbationSpain
Clinical Trials on Ciclesonide
-
University of ChicagoSunovionWithdrawnAllergic RhinitisUnited States
-
Hamilton Health Sciences CorporationTakeda; Kolding SygehusCompleted
-
SunovionCompleted
-
SunovionCompletedSeasonal Allergic RhinitisUnited States
-
SunovionCompletedAllergic Rhinitis | Perennial Allergic RhinitisUnited States
-
SunovionCompleted
-
SunovionCompletedSeasonal Allergic RhinitisUnited States
-
SunovionCompletedPerennial Allergic Rhinitis | PARUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States
-
Allergy & Asthma Medical Group & Research CenterCompleted